1.Date of occurrence of the event:2022/06/21
2.Company name:Adimmune Corporation
3.Relationship with the Company (please enter "the company itself" or
"subsidiaries"):The company itself
4.Reciprocal shareholding percentage:N/A
5.Name of the reporting media:Column A13 of Economic Daily News dated
2022/06/21
6.Content of the report:Adimmune is Expanding Its Global Market
Sales of Influenza Vaccine in China and Russia Boosted Performance in June.
Accessing Mexico and Latin America Market.
Adimmune Corporation (TPE: 4142) is expanding its global market. Boosted by
the sales of influenza vaccine antigen to Russia and QIV to China this year,
the performance of Q3 and Q4 is expected to be reflected in June and drive
the revenue of the month....
The influenza vaccine to China and Russia has been shipped starting from
June. The peak season is usually during Q3 and Q4, which may moved forward
to June this year. Institutional investors expect the monthly sales to show
a doubled year-over-year increase, while the annual sales may reach NT$2.5
billion....
7.Cause of occurrence: The sales of reporting were speculations by the press.
8.Countermeasures:
(1) The Company didn't provide nor reveal financial information. The
above-mentioned sales were speculations by the institutional investors.
For actual financial information and sales, the figures on MOPS shall take
precedence.
(2) The actual results of the above-mentioned reporting will be announced
under regulation through material informaion. Investors shall refer to the
actual information submitted under regulation by the Company to MOPS.
9.Any other matters that need to be specified:The Company has clarified
the media reporting as requested by TWSE on 2022/06/21.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Adimmune Corporation published this content on 21 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2022 08:03:05 UTC.
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
ADIMMUNE CORPORATION 
